This phase II study examined the efficacy of lenalidomide in combination with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R2CHOP) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

Patients (n = 64) with stage II-IV CD20+ DLBCL were enrolled in the study with 60 patients being evaluable for response. The molecular subtype of DLBCL was determined by tumour immunohistochemistry and classified as either germinal centre B-cell (GCB) or non-GCB in those receiving R2CHOP and 87 control patients with DLBCL from the Lymphoma Database who received R-CHOP only. The overall response rate was 98% (59 of 60) with 80% (48 of 60) achieving a complete response. At 24 months, event-free survival and overall survival (OS) rates were 59% (95% CI, 48% to 74%) and 78% (95% CI, 68% to 90%), respectively. In those receiving R-CHOP, 24-month progression-free survival and OS were 28% versus 64% (p<0.001) and 46% versus 78% (p<0.001) in non-GCB DLBCL versus GCB DLBCL, respectively. For more information, click here.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.